University of Oulu

Sikorski, V.; Karjalainen, P.; Blokhina, D.; Oksaharju, K.; Khan, J.; Katayama, S.; Rajala, H.; Suihko, S.; Tuohinen, S.; Teittinen, K.; Nummi, A.; Nykänen, A.; Eskin, A.; Stark, C.; Biancari, F.; Kiss, J.; Simpanen, J.; Ropponen, J.; Lemström, K.; Savinainen, K.; Lalowski, M.; Kaarne, M.; Jormalainen, M.; Elomaa, O.; Koivisto, P.; Raivio, P.; Bäckström, P.; Dahlbacka, S.; Syrjälä, S.; Vainikka, T.; Vähäsilta, T.; Tuncbag, N.; Karelson, M.; Mervaala, E.; Juvonen, T.; Laine, M.; Laurikka, J.; Vento, A.; Kankuri, E. Epitranscriptomics of Ischemic Heart Disease—The IHD-EPITRAN Study Design and Objectives. Int. J. Mol. Sci. 2021, 22, 6630. https://doi.org/10.3390/ijms22126630

Epitranscriptomics of ischemic heart disease : the IHD-EPITRAN study design and objectives

Saved in:
Author: Sikorski, Vilbert1; Karjalainen, Pasi2; Blokhina, Daria1;
Organizations: 1Department of Pharmacology, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland
2Heart and Lung Center, Helsinki University Hospital, 00029 Helsinki, Finland
3Tampere Heart Hospital, Tampere University Hospital, 33520 Tampere, Finland
4Folkhälsan Research Center, 00250 Helsinki, Finland
5Graduate School of Informatics, Department of Health Informatics, Middle East Technical University, 06800 Ankara, Turkey
6Heart Center, Turku University Hospital and Department of Surgery, University of Turku, 20521 Turku, Finland
7Research Unit of Surgery, Anesthesiology and Critical Care, University of Oulu, 90014 Oulu, Finland
8Clinical Biobank Tampere, Tampere University Hospital, 33520 Tampere, Finland
9Helsinki Institute of Life Science (HiLIFE), Meilahti Clinical Proteomics Core Facility, Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland
10Institute of Bioorganic Chemistry, Polish Academy of Sciences, Department of Biomedical Proteomics, 61-704 Poznan, Poland
11Chemistry Unit, Finnish Food Authority, 00790 Helsinki, Finland
12Helsinki Biobank, Hospital District of Helsinki and Uusimaa, 00029 Helsinki, Finland
13Department of Chemical and Biological Engineering, College of Engineering, Koç University, 34450 Istanbul, Turkey
14School of Medicine, Koç University, 34450 Istanbul, Turkey
15Institute of Chemistry, University of Tartu, 50411 Tartu, Estonia
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 2.8 MB)
Persistent link: http://urn.fi/urn:nbn:fi-fe2021112456824
Language: English
Published: Multidisciplinary Digital Publishing Institute, 2021
Publish Date: 2021-11-24
Description:

Abstract

Epitranscriptomic modifications in RNA can dramatically alter the way our genetic code is deciphered. Cells utilize these modifications not only to maintain physiological processes, but also to respond to extracellular cues and various stressors. Most often, adenosine residues in RNA are targeted, and result in modifications including methylation and deamination. Such modified residues as N-6-methyl-adenosine (m⁶A) and inosine, respectively, have been associated with cardiovascular diseases, and contribute to disease pathologies. The Ischemic Heart Disease Epitranscriptomics and Biomarkers (IHD-EPITRAN) study aims to provide a more comprehensive understanding to their nature and role in cardiovascular pathology. The study hypothesis is that pathological features of IHD are mirrored in the blood epitranscriptome. The IHD-EPITRAN study focuses on m⁶A and A-to-I modifications of RNA. Patients are recruited from four cohorts: (I) patients with IHD and myocardial infarction undergoing urgent revascularization; (II) patients with stable IHD undergoing coronary artery bypass grafting; (III) controls without coronary obstructions undergoing valve replacement due to aortic stenosis and (IV) controls with healthy coronaries verified by computed tomography. The abundance and distribution of m⁶A and A-to-I modifications in blood RNA are charted by quantitative and qualitative methods. Selected other modified nucleosides as well as IHD candidate protein and metabolic biomarkers are measured for reference. The results of the IHD-EPITRAN study can be expected to enable identification of epitranscriptomic IHD biomarker candidates and potential drug targets.

see all

Series: International journal of molecular sciences
ISSN: 1661-6596
ISSN-E: 1422-0067
ISSN-L: 1661-6596
Volume: 22
Issue: 12
Article number: 6630
DOI: 10.3390/ijms22126630
OADOI: https://oadoi.org/10.3390/ijms22126630
Type of Publication: A1 Journal article – refereed
Field of Science: 3111 Biomedicine
3121 General medicine, internal medicine and other clinical medicine
Subjects:
m6A
Funding: This research received funding by The Finnish Foundation for Cardiovascular Research (E.K.); Government-allocated block grants to specialty area (no. TYH2020340) (A.V.); Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research (no. 200174), The Finnish Medical Foundation (no. 3857) (V.S.); The Finnish Foundation for Cardiovascular Research (D.B.) and Jane and Aatos Erkko Foundation (S.K.).
Copyright information: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
  https://creativecommons.org/licenses/by/4.0/